Donald Trump’s $765 million, taxpayer-funded loan to Kodak, to start a pharmaceutical division, cries out for SEC and Congressional investigations.
August 5, 2020

I’ve written twice about the scandal lurking behind Trump’s very suspicious use of the Defense Production Act to loan Kodak $765 in taxpayer money to reconfigure itself as a pharmaceutical company – and, coincidentally greatly enrich its CEO at the same time, via well-timed stock options. It also just so happens that Kodak was a big sponsor of Trump's Celebrity Apprentice show.

Monday night, Joy Reid asked business correspondent Stephanie Ruhle, “What the heck is going on with this deal?”

RUHLE: Here’s why this deal stinks. Eastman Kodak filed for bankruptcy in 2011. Yes, it’s a huge storied company, with a huge American brand that squandered it. And in the age of digital, they lost their groove.

They filed in 2012. They tried to get their groove back and failed. They tried to get into the cryptocurrency space. But even in the last year, executives have been guiding Wall Street, saying, “We might not be able to continue much longer.” They issued a deal in the spring because they didn't have enough money.

So, here we are, a company with no pharmaceutical experience. Yes, they’ve got experience in making chemicals that had to do with developing film. No experience. So, if this administration wanted to say we're too dependent on getting drug ingredients from China, we want to bring it here, that makes a lot of sense. Guess what we have though, Joy? All sorts of viable drug companies that could do this. Eastman Kodak sure ain't one of them. That's my problem.

The supposed collateral for the loan is suspect, too. Although the company has emerged from bankruptcy, Ruhle questioned whether there's real assets protecting the public money given that the stock was trading at $2 a share before the loan was announced?

“Every lawmaker out there should be on the side of, at the very least, asking questions, as well as the SEC,” Ruhle said.

Reid raised the obvious question: Is there some kind of financial benefit to Trump in this deal?

Ruhle called it “premature” to draw such a conclusion but definitely time to start investigating.

RUHLE: Listen, it stinks to the high heavens. But is it premature to officially link the president or the executives of this company or their very large shareholders to the Trump administration? It's premature to say anything like that. But it is not premature to be asking the question and start digging. I promise you, Joy Reid, this story is not going away and we will continue to dig. It don't make sense.

UPDATE: The SEC is investigating. While I was writing this up, I found this further bit of stink, in an article about that in USA Today:

The details of the loan deal were revealed to local media outlets by the White House the day before the official announcement, which contributed to Kodak shares surging above $60. Shares of Kodak closed at $14.40 on Tuesday.

An earlier report said that Kodak had carelessly leaked the news. I'm not sure which is worse.

And then there's Trump:

Can you help us out?

For nearly 20 years we have been exposing Washington lies and untangling media deceit, but now Facebook is drowning us in an ocean of right wing lies. Please give a one-time or recurring donation, or buy a year's subscription for an ad-free experience. Thank you.


We welcome relevant, respectful comments. Any comments that are sexist or in any other way deemed hateful by our staff will be deleted and constitute grounds for a ban from posting on the site. Please refer to our Terms of Service for information on our posting policy.